Biologically Based Methods for Cancer Risk Assessment: NATO Science Series A:, cartea 159
Editat de Curtis Travisen Limba Engleză Paperback – 30 apr 2013
Din seria NATO Science Series A:
- 5%
Preț: 372.93 lei - 15%
Preț: 629.85 lei - 15%
Preț: 631.23 lei - 15%
Preț: 652.15 lei -
Preț: 382.30 lei - 5%
Preț: 363.51 lei -
Preț: 382.65 lei - 18%
Preț: 1184.45 lei - 5%
Preț: 703.40 lei -
Preț: 397.45 lei - 15%
Preț: 624.14 lei - 5%
Preț: 355.43 lei -
Preț: 392.06 lei -
Preț: 391.91 lei -
Preț: 381.34 lei - 15%
Preț: 638.29 lei -
Preț: 372.67 lei -
Preț: 378.21 lei -
Preț: 383.23 lei -
Preț: 385.99 lei - 15%
Preț: 652.60 lei -
Preț: 380.09 lei - 18%
Preț: 915.43 lei - 15%
Preț: 629.18 lei -
Preț: 386.74 lei -
Preț: 385.99 lei - 15%
Preț: 629.98 lei -
Preț: 379.71 lei -
Preț: 369.90 lei - 5%
Preț: 380.56 lei - 5%
Preț: 1366.27 lei - 15%
Preț: 626.20 lei -
Preț: 384.90 lei -
Preț: 372.31 lei - 5%
Preț: 371.42 lei -
Preț: 388.57 lei - 15%
Preț: 626.36 lei -
Preț: 378.95 lei - 5%
Preț: 362.13 lei -
Preț: 385.06 lei - 5%
Preț: 374.06 lei -
Preț: 385.44 lei - 5%
Preț: 711.99 lei - 18%
Preț: 1177.49 lei - 5%
Preț: 371.77 lei -
Preț: 405.77 lei
Preț: 363.18 lei
Preț vechi: 382.30 lei
-5%
Puncte Express: 545
Preț estimativ în valută:
64.26€ • 76.62$ • 55.89£
64.26€ • 76.62$ • 55.89£
Carte tipărită la comandă
Livrare economică 27 martie-10 aprilie
Specificații
ISBN-13: 9781468456271
ISBN-10: 146845627X
Pagini: 368
Ilustrații: IX, 355 p. 54 illus.
Dimensiuni: 178 x 254 x 19 mm
Greutate: 0.64 kg
Ediția:Softcover reprint of the original 1st ed. 1989
Editura: Springer Us
Colecția Springer
Seria NATO Science Series A:
Locul publicării:New York, NY, United States
ISBN-10: 146845627X
Pagini: 368
Ilustrații: IX, 355 p. 54 illus.
Dimensiuni: 178 x 254 x 19 mm
Greutate: 0.64 kg
Ediția:Softcover reprint of the original 1st ed. 1989
Editura: Springer Us
Colecția Springer
Seria NATO Science Series A:
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
Research Needs for Biologically Based Risk Assessment.- Biological Bases for Cancer Models.- Multistage Models for Cancer Risk Assessment.- Understanding Multi-Stage Carcinogenesis at the Molecular Level: Notes on Recent Progress.- The Use of Enzyme-Altered Foci for Risk Assessment of Hepatocarcinogens.- Pathogenic Interrelationship of Focal Lesions, Nodules, Adenomas and Carcinomas in the Multistage Evolution of Azaserine-Induced Rat Pancreas Carcinogenesis.- Phenotypic Cellular Changes in Multistage Carcinogenesis.- Interspecies Extrapolation of Pharmacokinetics.- Interspecies Extrapolation.- Comparative Carcinogenesis: Is There a Theoretical Approach to Inter-Species Similarity.- Biological Basis for Interspecies Extrapolations of Halogenated Solvents and of 1,3-Butadiene.- Species-Specific Inhalation Pharmacokinetics of 2-Nitropropane, Methyl Ethyl Ketone, and n-Hexane.- Promotion as a Factor in Carcinogenesis.- Overview of Promotion as a Mechanism in Carcinogenesis.- Hepatocarcinogenesis by Non-Genotoxic Compounds.- The Role of Inhibited Intercellular Communication in Carcinogenesis: Implications for Risk Assessment From Exposure to Chemicals.- Comparative Analyses of the Timing and Magnitude of Genotoxic and Nongenotoxic Cellular Effects in Urinary Bladder Carcinogenesis.- Alterations in Gene Expression in Mouse Hepatocarcinogenesis.- Screening for Carcinogenesis.- Medium-Term Bioassay Models for Environmental Carcinogens — Two — Step Liver and Multi-Organ Carcinogenesis Protocols.- The Use of Aldh Induction as a Carcinogenic Risk Marker in Comparison With Typical in Vitro Mutagenicity System.- Expression of Inducible Cytochrome P-450 mRNAs During Promotion of Expermential Chemical Hepatocarcinogenesis.- An In Vitro Approach for Interspecies ExtrapolationUsing Animal and Human Airway Epithelial Cell Culture.- Cancer Risk Assessment.- Assement of Low-Exposure Risk from Carcinogens: Implications of the Knudson-Moolgavkar Two-Critical Mutation Theory.- A Biological Data Base for Methylene Chloride Risk Assessment.- Computer Simulation of Chemical Carcinogenesis.- Determination of Carcinogen Exposure by Immunological Techniques.- Risk Estimation for Leukemogenic Drugs.- Contributors.